I-Mab Biopharma US Limited
12
2
2
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
33%
2 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
Role: lead
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
Role: lead
A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors
Role: lead
Nasal Protollin in Early Symptomatic Alzheimer's Disease
Role: collaborator
Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma
Role: lead
Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)
Role: lead
Expanded Access Study of TJ004309 in Patients With Advanced or Metastatic Cancer
Role: lead
A Study Evaluating TJ210001 in the Treatment of Subjects With Advanced Solid Tumors
Role: lead
Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors
Role: lead
Expanded Access Protocol for Subjects With Relapsed or Refractory Advanced Solid Tumors Receiving TJ210001
Role: lead
A Study of TJ003234 in Rheumatoid Arthritis Patients
Role: lead
Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Healthy Adult Subjects
Role: lead
All 12 trials loaded